CABA’s reсе-cel touts nine-day manufacturing and strong safety profile
Rese-cel’s nine-day manufacturing process and strong safety profile are highlighted in CAR-T for autoimmune diseases, with over 90 patients treated and no severe neurotoxicity or IEC-HS events.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.